Experienced in Tetanus

Amit Assa

14 Kaplan St, 4920235, 
Petah Tiqwa, M, IL 
Experienced in Tetanus
14 Kaplan St, 4920235, 
Petah Tiqwa, M, IL 
OverviewLocationsClinical Research

Overview

Amit Assa practices in Petah Tiqwa, Israel. Mr. Assa is rated as an Experienced expert by MediFind in the treatment of Tetanus. His top areas of expertise are Viral Gastroenteritis, Crohn's Disease, Colitis, Endoscopy, and Small Bowel Resection.

His clinical research consists of co-authoring 147 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Tetanus.

Gender
Male

Locations

14 Kaplan St, 4920235, Petah Tiqwa, M 49202, Israel
Other Locations
12 Shmuel Beit St, Jerusalem, JM 91031, Israel

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
Enrollment Status: Completed
Publish Date: December 27, 2024
Intervention Type: Drug
Study Drugs: Mirikizumab, Ustekinumab
Study Phase: Phase 3
A Multicenter, Open-Label PK Study of Mirikizumab in Pediatric Patients With Moderately to Severely Active Ulcerative Colitis
A Multicenter, Open-Label PK Study of Mirikizumab in Pediatric Patients With Moderately to Severely Active Ulcerative Colitis
Enrollment Status: Completed
Publish Date: March 26, 2024
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 2
Predicting Response to Vedolizumab in Pediatric Inflammatory Bowel Diseases (IBD) Including Drug Levels: a Multi-center Prospective Cohort Study, From the Pediatric IBD Porto Group of European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN)
Predicting Response to Vedolizumab in Pediatric Inflammatory Bowel Diseases (IBD) Including Drug Levels: a Multi-center Prospective Cohort Study, From the Pediatric IBD Porto Group of European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN)
Enrollment Status: Completed
Publish Date: October 25, 2022
Intervention Type: Drug
Study Drug: Vedolizumab
Study Phase: Not Applicable
Manipulating the Microbiome in IBD by Antibiotics and Fecal Microbiota Transplantation (FMT): a Randomized Controlled Trial
Manipulating the Microbiome in IBD by Antibiotics and Fecal Microbiota Transplantation (FMT): a Randomized Controlled Trial
Enrollment Status: Completed
Publish Date: October 08, 2021
Intervention Type: Drug
Study Drugs: Vancomycin, Amoxycillin, Doxycyline, Ciprofloxacin, Methylprednisolone, Metronidazole
Study Phase: Not Applicable
A Phase 3, Multicenter, Randomized, Double-blind Study to Determine the Safety and Efficacy of MMX Mesalamine/Mesalazine in Pediatric Subjects With Mild to Moderate Ulcerative Colitis, in Both Acute and Maintenance Phases
A Phase 3, Multicenter, Randomized, Double-blind Study to Determine the Safety and Efficacy of MMX Mesalamine/Mesalazine in Pediatric Subjects With Mild to Moderate Ulcerative Colitis, in Both Acute and Maintenance Phases
Enrollment Status: Completed
Publish Date: June 09, 2021
Intervention Type: Drug
Study Phase: Phase 3
View 4 Less Clinical Trials

147 Total Publications

Author's Reply: Comment on ``A switch to infliximab may be more effective than ustekinumab following adalimumab pharmacodynamic failure in paediatric patients with Crohn's disease''.
Author's Reply: Comment on ``A switch to infliximab may be more effective than ustekinumab following adalimumab pharmacodynamic failure in paediatric patients with Crohn's disease''.
Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
Published: September 25, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Assa's expertise for a condition
ConditionClose
View All 29 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile